Literature DB >> 26438394

Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?

Beatriz García-Fontana1, Rebeca Reyes-García1,2, Sonia Morales-Santana1,3, Verónica Ávila-Rubio1, Araceli Muñoz-Garach4, Pedro Rozas-Moreno1,5, Manuel Muñoz-Torres6.   

Abstract

Myostatin and irisin are two myokines related to energy metabolism, acting on skeletal muscle and recently suggested on adipose tissue in mice. However, the exact role of these myokines in humans has not been fully established. Our aim was to evaluate the relationship between serum levels of myostatin and irisin in type 2 diabetes mellitus patients and non-diabetic controls and to explore its links with metabolic parameters. Case-control study including 73 type 2 diabetes mellitus patients and 55 non-diabetic subjects as control group. Circulating myostatin and irisin levels were measured by enzyme-linked immunosorbent assays. Type 2 diabetes mellitus patients showed significantly lower myostatin levels (p = 0.001) and higher irisin levels (p = 0.036) than controls. An inverse relationship was observed between myostatin and irisin levels (p = 0.002). Moreover, in type 2 diabetes mellitus patients, after adjusting by confounder factors, myostatin was negatively related to fasting plasma glucose (p = 0.005) and to triglyceride levels (p = 0.028) while irisin showed a positive association with these variables (p = 0.017 and p = 0.006 respectively). A linear regression analysis showed that irisin and fasting plasma glucose levels were independently associated to myostatin levels and that myostatin and triglyceride levels were independently associated to irisin concentrations in type 2 diabetes mellitus patients. Our results suggest that serum levels of myostatin and irisin are related in patients with type 2 diabetes. Triglyceride and glucose levels could modulate myostatin and irisin concentrations as a compensatory mechanism to improve the metabolic state in these patients although further studies are needed to elucidate whether the action of these myokines represents an adaptative response.

Entities:  

Keywords:  Energy metabolism; Irisin; Myostatin; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2015        PMID: 26438394     DOI: 10.1007/s12020-015-0758-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  39 in total

1.  Metabolism: Irisin, the metabolic syndrome and follistatin in humans.

Authors:  Pontus A Boström; José Manuel Fernández-Real
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

2.  Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk.

Authors:  Grigorios Panagiotou; Lin Mu; Brian Na; Kenneth J Mukamal; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-06-09       Impact factor: 8.694

3.  Increased circulating myostatin in patients with type 2 diabetes mellitus.

Authors:  Fang Wang; Yonggan Liao; Xuefeng Li; Chunlin Ren; Changming Cheng; Yongsheng Ren
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

4.  Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery.

Authors:  Thomas Ebert; Holger Stepan; Susanne Schrey; Susan Kralisch; Janka Hindricks; Lisa Hopf; Martin Platz; Ulrike Lossner; Beate Jessnitzer; Sascha Drewlo; Matthias Blüher; Michael Stumvoll; Mathias Fasshauer
Journal:  Cytokine       Date:  2013-12-16       Impact factor: 3.861

5.  Relationship between circulating irisin, renal function and body composition in type 2 diabetes.

Authors:  Jian-Jun Liu; Sylvia Liu; Melvin D S Wong; Clara S H Tan; Subramaniam Tavintharan; Chee Fang Sum; Su Chi Lim
Journal:  J Diabetes Complications       Date:  2013-10-04       Impact factor: 2.852

6.  Myostatin regulates glucose metabolism via the AMP-activated protein kinase pathway in skeletal muscle cells.

Authors:  Yuewen Chen; Jianwei Ye; Lingzhi Cao; Yong Zhang; Weibo Xia; Dahai Zhu
Journal:  Int J Biochem Cell Biol       Date:  2010-09-29       Impact factor: 5.085

7.  Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients.

Authors:  Rocio de la Iglesia; Patricia Lopez-Legarrea; Ana B Crujeiras; Maria Pardo; Felipe F Casanueva; Maria A Zulet; Jose A Martinez
Journal:  Clin Endocrinol (Oxf)       Date:  2014-01-07       Impact factor: 3.478

8.  Lower circulating irisin is associated with type 2 diabetes mellitus.

Authors:  Jian-Jun Liu; Melvin D S Wong; Wan Ching Toy; Clara S H Tan; Sylvia Liu; Xiao Wei Ng; Subramaniam Tavintharan; Chee Fang Sum; Su Chi Lim
Journal:  J Diabetes Complications       Date:  2013-04-22       Impact factor: 2.852

9.  Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies.

Authors:  Timea Kurdiova; Miroslav Balaz; Marek Vician; Denisa Maderova; Miroslav Vlcek; Ladislav Valkovic; Miroslav Srbecky; Richard Imrich; Olga Kyselovicova; Vitazoslav Belan; Ivan Jelok; Christian Wolfrum; Iwar Klimes; Martin Krssak; Erika Zemkova; Daniela Gasperikova; Jozef Ukropec; Barbara Ukropcova
Journal:  J Physiol       Date:  2013-12-02       Impact factor: 5.182

Review 10.  Regulation of muscle mass by myostatin.

Authors:  Se-Jin Lee
Journal:  Annu Rev Cell Dev Biol       Date:  2004       Impact factor: 13.827

View more
  17 in total

Review 1.  Implications of exercise-induced adipo-myokines in bone metabolism.

Authors:  Giovanni Lombardi; Fabian Sanchis-Gomar; Silvia Perego; Veronica Sansoni; Giuseppe Banfi
Journal:  Endocrine       Date:  2015-12-30       Impact factor: 3.633

Review 2.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

3.  Irisin and Visfatin Predicts Severity of Diabetic Nephropathy.

Authors:  Ramalingam Mageswari; M G Sridhar; H Nandeesha; Sreejith Parameshwaran; K V Vinod
Journal:  Indian J Clin Biochem       Date:  2018-03-21

Review 4.  Does iris(in) bring bad news or good news?

Authors:  Silvio Buscemi; Davide Corleo; Carola Buscemi; Carla Giordano
Journal:  Eat Weight Disord       Date:  2017-09-20       Impact factor: 4.652

5.  Myostatin serum levels in children with type 1 diabetes mellitus.

Authors:  Alexandra Efthymiadou; Ioannis-Anargyros Vasilakis; Aristeidis Giannakopoulos; Dionisios Chrysis
Journal:  Hormones (Athens)       Date:  2021-09-06       Impact factor: 2.885

6.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

7.  Serum Myostatin and IGF-1 as Gender-Specific Biomarkers of Frailty and Low Muscle Mass in Community-Dwelling Older Adults.

Authors:  J Chew; L Tay; J P Lim; B P Leung; A Yeo; S Yew; Y Y Ding; W S Lim
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

8.  Factors associated with circulating concentrations of irisin in the general population cohort of the ABCD study.

Authors:  S Buscemi; D Corleo; S Vasto; C Buscemi; M F Massenti; D Nuzzo; G Lucisano; A M Barile; G Rosafio; V Maniaci; C Giordano
Journal:  Int J Obes (Lond)       Date:  2017-10-13       Impact factor: 5.095

9.  Long-term GABA administration improves FNDC5, TFAM, and UCP3 mRNA expressions in the skeletal muscle and serum irisin levels in chronic type 2 diabetic rats.

Authors:  Farzaneh Yazdanimoghaddam; Maedeh Ghasemi; Hanif Teamparvar; Nepton Soltani; Mahmoud Aghaei; Hossein Rezazadeh; Fouzieh Zadhoush
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-02-02       Impact factor: 3.000

10.  Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.

Authors:  Hajime Yamakage; Masashi Tanaka; Takayuki Inoue; Shinji Odori; Toru Kusakabe; Noriko Satoh-Asahara
Journal:  J Diabetes Investig       Date:  2019-12-10       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.